Highest-materiality recent filing
Senseonics Q2 revenue $14.5M (+120% YoY); raises FY2026 guidance to $62-66M
Q2 revenue $14.5M, up 120% YoY; U.S. revenue $12.6M (+150% YoY).
Closings on June 1, 2026 for Germany, Spain, Sweden; Italy closed June 8, 2026 with effective date June 1, 2026.
Senseonics shareholders approve doubling authorized shares to 140M
Increase authorized common stock from 70M to 140M shares, effective May 20, 2026.
Senseonics Q1 revenue up 87% to $11.7M; raises FY2026 guidance to $60-64M
Q1 revenue $11.7M (+87% YoY); US $9.3M, OUS $2.4M.
Senseonics amends loan agreement; up to $140M total, $20M expected to fund May 6
Amended loan agreement with Hercules Capital expands total commitment to $140M, with $80M committed and $60M uncommitted.
Senseonics prices $80M public offering, reports preliminary Q1 revenue $11.7M and net loss $31-33M
Offering: 8M shares + 8M pre-funded warrants at $5.00; net proceeds ~$74.7M ($86M if overallotment exercised). Underwriters have 30-day option for 2.4M additional shares.
On March 12, 2026, Senseonics entered into Local Purchase Agreements to acquire Ascensia's Eversense CGM assets in four European countries.
Senseonics Q4 revenue $14.3M (+72% YoY); guides FY26 revenue $58-62M
Q4 2025 revenue $14.3M (+72% YoY); US revenue $12.1M vs $6.2M in Q4 2024.
Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M
Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.
Senseonics closes $1.1M acquisition of U.S. Eversense assets from Ascensia
U.S. asset purchase closed Jan 1, 2026; cash consideration ~$1.1M for inventory, licenses, and leases.
Senseonics Q3 revenue $8.1M (+90% YoY); guides FY25 rev ~$35M; planning commercial transition
Q3 revenue $8.1M vs $4.3M YoY; U.S. revenue $6.4M (+167% YoY).
Senseonics Holdings announces 1-for-20 reverse stock split effective October 17, 2025
Reverse stock split ratio is 1-for-20, combining every 20 shares into 1.
Senseonics reports preliminary Q3 2025 revenue of ~$8.1M, up 91% YoY
Preliminary unaudited Q3 2025 revenue of approximately $8.1 million versus $4.2 million in Q3 2024.
Senseonics Q3 preliminary revenue $8.1M (+91% YoY); 1:20 reverse stock split effective Oct 17
Preliminary unaudited revenue $8.1M for Q3 2025, up 91% vs Q3 2024.
Senseonics shareholders approve reverse stock split of 1-for-10 to 1-for-20
Approved at special meeting on Sept 29, 2025; votes: 285.6M for, 178.2M against, 5.0M abstain.
Senseonics to take Eversense commercialization in-house, expands debt to $100M
MOU with Ascensia to transfer global Eversense commercialization to Senseonics by Jan 1, 2026; assets bought at book value.
Senseonics Q2 revenue $6.6M (+37% YoY); net loss narrows to $14.5M
Revenue $6.6M, up 37% YoY, driven by 79% U.S. new patient starts growth to $4.9M.
Senseonics shareholders elect directors, approve say-on-pay and KPMG ratification
Four director nominees elected: DeFalco, Hansen, Prince, Roeder; broker non-votes ~177M each.
Senseonics files technical amendment to prior 8-K; no new material information
Amendment to Form 8-K filed May 16, 2025, dated May 15, 2025.
Public offering of 100M shares priced at $0.50/share, with 15M-share overallotment option to underwriters.
Senseonics enters $25M private placement with Abbott; terminates ATM program
Up to $25M of common stock sold to Abbott at public offering price, closing within 2 days after public offering.
Senseonics Q1 revenue $6.3M, up 24% YoY; net loss narrows to $14.3M
Revenue $6.3M vs $5.0M YoY (+24%); U.S. $4.5M, OUS $1.8M.
Senseonics Q4 revenue $8.3M, net loss $15.5M; guides FY25 revenue $34-38M
Q4 revenue $8.3M (up from $8.0M YoY); net loss $15.5M ($0.02 loss per share).
Director Anthony Raab resigns from Senseonics board effective Jan. 17, 2025
Anthony Raab notified the Board of his resignation on January 17, 2025.
Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.
Senseonics updates corporate presentation at Stifel Healthcare Conference
Presentation highlights Eversense 365 CGM system FDA clearance and commercial launch.
Senseonics Q3 revenue $4.3M, gross loss $4.1M; Eversense 365 launch underway
Total revenue $4.3M, down ~30% YoY from $6.1M; U.S. revenue $2.4M vs $3.9M.
Senseonics prices $16M registered direct offering at $0.35/share with warrants
45,714,286 shares and matching warrants sold at combined $0.35 per unit.
Q2 revenue $4.9M (+18% YoY), net loss $20.3M; 365-day Eversense Q4 launch on track
Q2 2024 revenue $4.9M, up 18% vs $4.1M in Q2 2023; U.S. revenue $3.0M (+67%), OUS $1.9M.
Senseonics sees H1 2024 net rev $10M, +21% YoY; FY 2024 guidance $22-24M
Reaffirmed H1 2024 global net revenue $10M, 21% growth over H1 2023.
Senseonics stockholders approve increase in authorized common shares from 900M to 1.4B
Amendment to certificate of incorporation increases authorized common stock from 900M to 1.4B shares.
Senseonics Q1 revenue up 22% to $5.1M; net loss $18.9M vs income $1.3M
Revenue $5.1M (+22% YoY); U.S. $3.7M (+76%), OUS $1.4M (-30%).
Robert Schumm resigns from Senseonics board; PHC designee Brian Hansen appointed March 20
Robert Schumm resigned as director effective March 19, 2024, on PHC's reassignment; no disagreement with company.
Senseonics Q4 revenue $8.0M (+44% YoY); net loss $17.2M; 365-day FDA submission planned
Q4 2023 revenue $8.0M vs $5.6M Q4 2022; full-year revenue $22.4M (+37% YoY).
Senseonics draws $10M second tranche of $50M loan from Hercules Capital
Tranche 2 loan of $10M funded on Jan 2, 2024 under existing Loan and Security Agreement.
Senseonics Q3 revenue $6.1M, net loss narrows; secures $50M non-dilutive loan facility
Revenue $6.1M (+33% YoY); US revenue $3.9M (doubled from $1.9M); OUS $2.2M (down from $2.7M).
Senseonics enters $50M loan facility with Hercules Capital, exchanges $30.8M notes for equity
Up to $50M senior secured term loans; initial $25M funded Sept 8, 2023; additional tranches of $10M and $15M subject to conditions.
Senseonics Q2 revenue up 11% to $4.1M, net loss $20.4M; reiterates FY23 guidance
Revenue $4.1M vs $3.7M in Q2 2022; U.S. revenue $1.8M vs $1.2M.
Senseonics shareholders elect all five director nominees at 2023 annual meeting
All five director nominees elected: Goodnow, Kaufman, Larkin, Sato, Schumm, with broker non-votes ~161M.
Senseonics Q1 revenue $4.1M, up 64% YoY; reaffirms FY 2023 guidance $20-24M
Revenue $4.1M ($2.1M US, $2.0M OUS) vs $2.5M YoY; US rev more than doubled.
Senseonics exchanges $35M convertible notes for pre-funded warrant, issuing 68.5M shares to PHC
Exchanged $35M principal plus accrued interest on convertible notes due Oct 2024 for pre-funded warrant to purchase 68,525,311 shares.
Senseonics Q4 revenue $5.6M; FY revenue $16.4M; guides FY23 $20-24M
Q4 2022 revenue $5.6M vs $4.0M YoY; full-year revenue $16.4M vs $13.7M.
Senseonics raises $15M via warrant sale to PHC; exchanges $35M notes for additional warrants
Issued pre-funded warrant for 15,425,750 shares at ~$0.97/share to PHC, gross proceeds $15M.
Senseonics adopts 2023 Commercial Equity Plan for partner Ascensia employees; up to 10M shares
Board adopted 2023 Commercial Equity Plan on Jan 10, 2023 to grant stock options and RSUs to employees of commercial partner Ascensia Diabetes Care.
Senseonics sells $12M Series B Preferred to Energy Capital under 2020 equity line
Energy Capital exercised its right to purchase $12.0M of Series B Convertible Preferred Stock on Nov 7, 2022.
Senseonics Q3 revenue $4.6M (+31% YoY); net loss $60.4M on non-cash fair value adjustments
Revenue $4.6M vs $3.5M a year ago; U.S. revenue $1.9M (up from $0.6M), OUS $2.7M.
Senseonics CFO Nicholas Tressler steps down; Rick Sullivan named CFO effective Sept 1, 2022
Tressler will serve as advisor through Dec 31, 2022, then receive 8 months' severance plus pro-rata 2022 bonus.
Senseonics Q2 revenue $3.7M, net income $104.2M on fair value adjustments; reaffirms FY 2022 outlook
Revenue $3.7M, up from $3.3M YoY; US $1.2M, OUS $2.5M.
Senseonics stockholders elect three directors, approve say-on-pay, ratify KPMG as auditor
All three director nominees (DeFalco, Prince, Roeder) elected with 78-81M votes for; significant broker non-votes.
Senseonics Q1 revenue $2.5M; FDA approves Eversense E3 6-month CGM
Q1 2022 total revenue $2.5M vs $2.8M YoY; U.S. revenue $0.8M up from $0.3M.
On January 17, 2025, Anthony Raab, a director of Senseonics Holdings, Inc. (the “Company”) notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective as of January 17, 2025, in order to focus on his time commitments to his professional investment career, other board roles and family.
On March 20, 2024, the Board appointed Brian Hansen to serve as a director of the Company.
On March 19, 2024, Robert Schumm, a director of Senseonics Holdings, Inc. (the “Company”) who was designated to serve as a director of the Company by PHC Holdings Corporation (“PHC”), notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective March 19, 2024.
Effective September 1, 2022 (the “ Effective Date ”), the Board of Directors of the Company (the “ Board ”) appointed Frederick (“ Rick”) Sullivan as the Company’s Chief Financial Officer (in which capacity he will serve as the Company’s principal financial officer and principal accounting officer).
On August 30, 2022, Nicholas B. Tressler and Senseonics Holdings, Inc. (the “ Company ”) mutually agreed that Mr. Tressler would transition from his role as the Company’s Chief Financial Officer effective as of September 1, 2022.
On December 8, 2021, the board of directors (the “Board”) of Senseonics Holdings, Inc. (the “Company”) appointed Sharon Larkin to serve as a director of the Company, which appointment became effective immediately.
appointed John Marotta to serve as a director of the Company, which appointment became effective immediately.
Max materiality 0.85 · Median 0.70 · Most common event earnings